Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:03:23.773Z.
Consensus retrieved: 2026-10-06T13:18:41.647Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:03:23.773Z.
Quote observation: 2026-10-06T15:00:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0aae41c25609cbe98cd8c59fbdc20e812e1ea61d6a67e0b8df2c56749153647
Forward PE Ratio (N/A) = Dated Quote Price ($6.32) / Consensus Forward EPS ($-2.76)
FORWARD PE RATIO
N/A
Kyverna Therapeutics, Inc.
Market Cap
$384.23M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $384.23M | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $383.60M | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $380.42M | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $388.72M | N/A |
| Canopy Growth Corporation (CGC)vs › | $373.18M | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $403.47M | N/A |
| Carlsmed, Inc. (CARL)vs › | $406.14M | N/A |
| Neurogene Inc. (NGNE)vs › | $409.28M | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.08M | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $411.45M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.32, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.76 | $-2.82 – $-2.68 | 5 | n/m |
| 2027-12-31 | $-3.12 | $-3.62 – $-2.86 | 5 | n/m |
| 2028-12-31 | $-2.64 | $-3.90 – $-1.28 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
